Oscar Health slides as insider selling fuels profit-taking after recent run-up

Oscar Health, Inc. (OSCR) is down 5.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop looks most consistent with near-term profit-taking tied to fresh insider-selling disclosures, after OSCR’s sharp post-earnings run-up earlier in May. With no major new operational update from the company today, the selling pressure appears more sentiment- and positioning-driven than fundamentals-driven.

Details:

A recent insider filing showed CFO Richard Scott Blackley sold 110,000 shares in an open-market transaction on May 18, 2026, at a weighted average price around $25.03 (often interpreted as a negative signal after a quick rally).

Another filing disclosed additional May insider sales activity by the same executive earlier in the month, adding to the perception of supply hitting the market.

Oscar’s most recent quarterly update (released May 6, 2026) highlighted strong Q1 2026 results and included a reaffirmation of its full-year 2026 outlook, which had helped lift shares in the days that followed.

This could also be a normal pullback after a rapid advance, with traders locking in gains while the stock digests the earnings reset and insider-sale headlines.

Sources:

SEC, Stock Titan, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$OSCR Insider Trading Activity

$OSCR insiders have traded $OSCR stock on the open market 19 times in the past 6 months. Of those trades, 1 have been purchases and 18 have been sales.

Here’s a breakdown of recent trading of $OSCR stock by insiders over the last 6 months:

MARK T BERTOLINI (Chief Executive Officer) purchased 1,000,000 shares for an estimated $11,920,000
MARIO SCHLOSSER (President of Technology & CTO) has made 0 purchases and 7 sales selling 421,996 shares for an estimated $6,609,401.
RICHARD SCOTT BLACKLEY (Chief Financial Officer) has made 0 purchases and 5 sales selling 254,356 shares for an estimated $5,743,690.
ADAM MCANANEY (Chief Legal Officer) has made 0 purchases and 2 sales selling 20,562 shares for an estimated $281,251.
JANET LIANG (President, Oscar Insurance) has made 0 purchases and 2 sales selling 14,791 shares for an estimated $221,533.
VICTORIA BALTRUS (Chief Accounting Officer) has made 0 purchases and 2 sales selling 8,787 shares for an estimated $130,934.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$OSCR Hedge Fund Activity

We have seen 176 institutional investors add shares of $OSCR stock to their portfolio, and 212 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 5,422,772 shares (-65.3%) from their portfolio in Q4 2025, for an estimated $77,925,233
D. E. SHAW & CO., INC. added 4,500,503 shares (+283.6%) to their portfolio in Q4 2025, for an estimated $64,672,228
CAPITAL WORLD INVESTORS removed 3,622,586 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $52,056,560
MORGAN STANLEY removed 3,459,065 shares (-50.8%) from their portfolio in Q1 2026, for an estimated $39,675,475
JANE STREET GROUP, LLC removed 2,877,721 shares (-49.8%) from their portfolio in Q1 2026, for an estimated $33,007,459
TWO SIGMA ADVISERS, LP added 2,472,800 shares (+inf%) to their portfolio in Q4 2025, for an estimated $35,534,136
BANK OF AMERICA CORP /DE/ added 1,922,732 shares (+205.1%) to their portfolio in Q1 2026, for an estimated $22,053,736

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$OSCR Analyst Ratings

Wall Street analysts have issued reports on $OSCR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 11/26/2025

To track analyst ratings and price targets for $OSCR, check out Quiver Quantitative's $OSCR forecast page.

$OSCR Price Targets

Multiple analysts have issued price targets for $OSCR recently. We have seen 6 analysts offer price targets for $OSCR in the last 6 months, with a median target of $19.5.

Here are some recent targets:

Michael Ha from Baird set a target price of $19.0 on 05/07/2026
Andrew Mok from Barclays set a target price of $21.0 on 05/07/2026
Jonathan Yong from UBS set a target price of $20.0 on 05/07/2026
David Windley from Jefferies set a target price of $16.0 on 04/20/2026
Dean Sublett from Stephens & Co. set a target price of $17.0 on 12/11/2025
Jessica Tassan from Piper Sandler set a target price of $25.0 on 11/26/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.